Clinical bottom line
Complement inhibitors represent a promising therapeutic avenue for C3 glomerulopathy (C3G), a rare complement-mediated kidney disease characterized by dysregulation of the alternative complement pathway. Current evidence supports the use of complement blockade, particularly targeting C5 and C3 components, to reduce disease activity and preserve renal function in selected patients. However, responses are variable and long-term efficacy and safety data remain limited. Complement inhibition should be considered within a multidisciplinary framework and tailored to individual patient profiles, pending further controlled trials to define optimal agents and treatment duration (Noris et al., 2024; Meuleman et al., 2022).
What the evidence shows
Noris et al. (2024) provide an updated overview of treatment standards for C3G and immune-complex membranoproliferative glomerulonephritis (Ig-MPGN), emphasizing complement inhibition as a key emerging strategy. They highlight that while immunosuppressive therapies have limited efficacy, complement blockers targeting C5 (e.g., eculizumab) have shown promise in reducing proteinuria and stabilizing renal function in some patients.
Meuleman et al. (2022) review C3-targeted therapies, discussing novel agents that inhibit proximal complement activation. These therapies aim to more specifically address the underlying pathophysiology of C3G by preventing C3 convertase formation and subsequent glomerular deposition, potentially offering improved outcomes over C5 blockade.
Goodship et al. (2017), from a KDIGO controversies conference, underscore the heterogeneity of C3G and the need for individualized treatment approaches. They note that complement inhibition is rational but that evidence is largely from case series and small cohorts, necessitating further research.
Mirioglu et al. (2025) summarize novel complement blockade strategies, including emerging C3 inhibitors and factor B inhibitors, which may provide more targeted and effective control of complement dysregulation in C3G.
Apetrii et al. (2025) provide a broader update on complement inhibitors in nephrology, reinforcing the potential of these agents in complement-mediated diseases including C3G, while discussing challenges such as infection risk and treatment cost.
Caveats and uncertainty
Most clinical evidence derives from small observational studies, case reports, or open-label trials, limiting generalizability.
Heterogeneity in disease presentation and complement abnormalities complicates patient selection and response prediction.
Long-term safety, especially regarding infection risk due to complement blockade, requires careful monitoring.
Optimal timing, dosing, and duration of complement inhibitor therapy remain undefined.
Cost and accessibility of complement inhibitors may limit widespread use.
Combination with immunosuppressive agents and impact on transplant outcomes need further study.
How this may change practice
Nephrologists should consider complement inhibitors for patients with biopsy-proven C3G exhibiting active disease and progressive renal impairment, especially when conventional therapies fail.
Comprehensive complement profiling may guide personalized therapy selection and monitoring.
Multidisciplinary collaboration including nephrology, pathology, and immunology is essential for optimal management.
Clinicians should counsel patients on potential risks, including serious infections, and implement vaccination strategies.
Participation in clinical trials is encouraged to advance evidence on efficacy and safety.
Future practice may incorporate novel proximal complement inhibitors as they become clinically available.